NEW YORK, NY / ACCESS Newswire / January 8, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ:AGIO) concerning possible violations of federal securities laws. On November 19, 2025, Agios reported topline results from its RISE UP Phase 3 trial of Mitapivat in […]

NEW YORK, NY / ACCESS Newswire / January 8, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation of PagerDuty, Inc. ("PagerDuty, Inc.") (NYSE:PD) concerning possible violations of federal securities laws. On the evening of November 25, 2025, PagerDuty published results for the third quarter of fiscal 2026, disclosing a reduction

Vancouver, British Columbia–(Newsfile Corp. – January 8, 2026) – Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the “Company”) is pleased to announce it has exercised its buyback right to retire the 1% net smelter royalty (“NSR”) that applied to its Slovakian portfolio. The 1% NSR covered three mineral properties, including the flagship Trojarová Antimony

Vancouver, British Columbia–(Newsfile Corp. – January 8, 2026) – Perseverance Metals Inc. (TSXV: PMI) (“Perseverance“, “PMI” or the “Company“) is very pleased to provide assay results from six additional diamond drill holes (BAS-25-003 to 008), including 2.1m of massive sulphides previously announced. These holes were drilled to target Ni-Cu-Co-PGE magmatic sulphide mineralization within the Baseline Zone Discovery, part

(NASDAQ:AGMH), NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — AGM Group Holdings Inc. (“AGM Holdings” or the “Company”) (NASDAQ: AGMH), an integrated technology company specializing in the assembling and sales of high-performance hardware and computing equipment, today announced that it has entered into a Memorandum of Understanding (“MOU”) with Amber Premium, a global leading digital

(NasdaqGM:ACRV), Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with less-than or equal to2 prior lines of therapy* Analysis of data from all-comer subjects with serous subtype and less-than or equal

Financing supports Phase 2 development of ALV-100, IND filing of ALV-200 and advancement of additional programs across the R&D pipeline ALV-100, a bifunctional GIPR antagonist / GLP-1R agonist, designed for durable weight management with improved quality of weight loss and long-term maintenance Differentiated amylin-based pipeline, including an AMYR3 peptide agonist (ALV-200) and oral small molecule

(NASDAQ:ZENA),(Boerse Frankfurt – Freiverkehr:49Q),(BMV:ZENA), VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS, and Quantum Computing solutions, today announces it has completed its 20th acquisition. The most recent acquisition

(NASDAQ:PSTV), HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, announces the completion of a Type B meeting with the U.S. Food and Drug Administration (FDA) on next steps on REYOBIQ pivotal

(TSX-V:ELBM),(NASDAQ:ELBM), TORONTO, Jan. 08, 2026 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”), a leader in advancing North America's critical minerals processing, is pleased to provide an update on construction progress at North America's first cobalt sulfate refinery. “Momentum continues to build across the project,” said Paolo Toscano,